Literature DB >> 18587327

Salivary gland-type lung carcinomas: an EGFR immunohistochemical, molecular genetic, and mutational analysis study.

Ricardo S Macarenco1, Timothy S Uphoff, Heather Flynn Gilmer, Robert B Jenkins, Stephen N Thibodeau, Jean E Lewis, Julian R Molina, Ping Yang, Marie-Christine Aubry.   

Abstract

Salivary gland-type lung carcinomas are uncommon neoplasms of the lung, the two most common being adenoid cystic carcinoma and mucoepidermoid carcinoma. Although they usually have an indolent behavior, adenoid cystic carcinomas can be more aggressive, with 5-year survival as low as 55%. Unfortunately, these tumors do not respond well to chemotherapy. In contrast to the most common subtypes of lung carcinomas, epidermal growth factor receptor studies have not been carried out in this group of tumors. Herein we report a series of 24 cases (12 adenoid cystic and 12 mucoepidermoid carcinomas) tested for epidermal growth factor receptor protein expression, epidermal growth factor receptor gene copy gains, and epidermal growth factor receptor gene mutational status, through immunohistochemistry, fluorescence in situ hybridization, and sequencing of the exons 18-21, respectively. Overall, 91 and 92% of the adenoid cystic carcinomas and mucoepidermoid carcinomas expressed epidermal growth factor receptor protein. Chromosome 7 polysomy occurred in 25% of the cases (four adenoid cystic carcinomas and two mucoepidermoid carcinomas). No epidermal growth factor receptor gene amplification was detected and no mutation was found in exons 18-21 of the epidermal growth factor receptor gene. Immunoexpression of epidermal growth factor receptor in salivary gland-type lung carcinomas is not related to epidermal growth factor receptor gene copy number or mutational status.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18587327      PMCID: PMC2752817          DOI: 10.1038/modpathol.2008.113

Source DB:  PubMed          Journal:  Mod Pathol        ISSN: 0893-3952            Impact factor:   7.842


  40 in total

1.  Increased epidermal growth factor receptor gene copy number detected by fluorescence in situ hybridization associates with increased sensitivity to gefitinib in patients with bronchioloalveolar carcinoma subtypes: a Southwest Oncology Group Study.

Authors:  Fred R Hirsch; Marileila Varella-Garcia; Jason McCoy; Howard West; Ana Carolina Xavier; Paul Gumerlock; Paul A Bunn; Wilbur A Franklin; John Crowley; David R Gandara
Journal:  J Clin Oncol       Date:  2005-07-05       Impact factor: 44.544

2.  Erlotinib in lung cancer - molecular and clinical predictors of outcome.

Authors:  Ming-Sound Tsao; Akira Sakurada; Jean-Claude Cutz; Chang-Qi Zhu; Suzanne Kamel-Reid; Jeremy Squire; Ian Lorimer; Tong Zhang; Ni Liu; Manijeh Daneshmand; Paula Marrano; Gilda da Cunha Santos; Alain Lagarde; Frank Richardson; Lesley Seymour; Marlo Whitehead; Keyue Ding; Joseph Pater; Frances A Shepherd
Journal:  N Engl J Med       Date:  2005-07-14       Impact factor: 91.245

3.  Gefitinib plus best supportive care in previously treated patients with refractory advanced non-small-cell lung cancer: results from a randomised, placebo-controlled, multicentre study (Iressa Survival Evaluation in Lung Cancer).

Authors:  Nick Thatcher; Alex Chang; Purvish Parikh; José Rodrigues Pereira; Tudor Ciuleanu; Joachim von Pawel; Sumitra Thongprasert; Eng Huat Tan; Kristine Pemberton; Venice Archer; Kevin Carroll
Journal:  Lancet       Date:  2005 Oct 29-Nov 4       Impact factor: 79.321

4.  Protein expression and gene amplification of epidermal growth factor receptor in thymomas.

Authors:  Diana N Ionescu; Elizaburo Sasatomi; Kathleen Cieply; Marin Nola; Sanja Dacic
Journal:  Cancer       Date:  2005-02-01       Impact factor: 6.860

5.  Epidermal growth factor receptor expression status in lung cancer correlates with its mutation.

Authors:  Makoto Suzuki; Hisayuki Shigematsu; Kenzo Hiroshima; Toshihiko Iizasa; Yukio Nakatani; John D Minna; Adi F Gazdar; Takehiko Fujisawa
Journal:  Hum Pathol       Date:  2005-10       Impact factor: 3.466

6.  Epidermal growth factor receptor gene and protein and gefitinib sensitivity in non-small-cell lung cancer.

Authors:  Federico Cappuzzo; Fred R Hirsch; Elisa Rossi; Stefania Bartolini; Giovanni L Ceresoli; Lynne Bemis; Jerry Haney; Samir Witta; Kathleen Danenberg; Irene Domenichini; Vienna Ludovini; Elisabetta Magrini; Vanesa Gregorc; Claudio Doglioni; Angelo Sidoni; Maurizio Tonato; Wilbur A Franklin; Lucio Crino; Paul A Bunn; Marileila Varella-Garcia
Journal:  J Natl Cancer Inst       Date:  2005-05-04       Impact factor: 13.506

7.  Clinical and biological features associated with epidermal growth factor receptor gene mutations in lung cancers.

Authors:  Hisayuki Shigematsu; Li Lin; Takao Takahashi; Masaharu Nomura; Makoto Suzuki; Ignacio I Wistuba; Kwun M Fong; Huei Lee; Shinichi Toyooka; Nobuyoshi Shimizu; Takehiko Fujisawa; Ziding Feng; Jack A Roth; Joachim Herz; John D Minna; Adi F Gazdar
Journal:  J Natl Cancer Inst       Date:  2005-03-02       Impact factor: 13.506

8.  Limited nonrandom chromosomal aberrations in a recurrent adenoid cystic carcinoma of the parotid gland.

Authors:  A K el-Naggar; M Lovell; D L Callender; A M Killary
Journal:  Cancer Genet Cytogenet       Date:  1999-02

9.  EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy.

Authors:  J Guillermo Paez; Pasi A Jänne; Jeffrey C Lee; Sean Tracy; Heidi Greulich; Stacey Gabriel; Paula Herman; Frederic J Kaye; Neal Lindeman; Titus J Boggon; Katsuhiko Naoki; Hidefumi Sasaki; Yoshitaka Fujii; Michael J Eck; William R Sellers; Bruce E Johnson; Matthew Meyerson
Journal:  Science       Date:  2004-04-29       Impact factor: 47.728

10.  Multiple reciprocal translocations in salivary gland mucoepidermoid carcinomas.

Authors:  Giovanni Tonon; Kristen Stover Gehlhaus; Raluca Yonescu; Frederic J Kaye; Ilan R Kirsch
Journal:  Cancer Genet Cytogenet       Date:  2004-07-01
View more
  22 in total

1.  Pulmonary mucoepidermoid carcinoma in Chinese population: a clinicopathological and radiological analysis.

Authors:  Mengge Wang; Songyun Ouyang; Peizong Sun; Daoming Li; Gongcheng Huang
Journal:  Int J Clin Exp Pathol       Date:  2015-03-01

2.  Mutational landscape and clonal diversity of pulmonary adenoid cystic carcinoma.

Authors:  Min Li; Bing-Rong Zhao; Shi-Qing Liu; Jian An; Peng-Bo Deng; Han Han-Zhang; Jun-Yi Ye; Xin-Ru Mao; Shao-Kun Chuai; Cheng-Ping Hu
Journal:  Cancer Biol Ther       Date:  2018-08-01       Impact factor: 4.742

3.  EGFR status and KRAS/BRAF mutations in intestinal-type sinonasal adenocarcinomas.

Authors:  Cristina García-Inclán; Fernando López; Jhudit Pérez-Escuredo; Mari Paz Cuesta-Albalad; Blanca Vivanco; Irene Centeno; Milagros Balbín; Carlos Suárez; José Luis Llorente; Mario A Hermsen
Journal:  Cell Oncol (Dordr)       Date:  2012-10-11       Impact factor: 6.730

4.  pEGFR-Tyr 845 expression as prognostic factors in oral squamous cell carcinoma: a tissue-microarray study with clinic-pathological correlations.

Authors:  Gabriella Aquino; Giuseppe Pannone; Angela Santoro; Giuseppina Liguori; Renato Franco; Rosario Serpico; Gianluca Florio; Alfredo De Rosa; Marilena Mattoni; Valentina Cozza; Gerardo Botti; Simona Losito; Francesco Longo; Stefania Staibano; Giovanni Cuda; Lorenzo Lo Muzio; Carolina Sbordone; Pantaleo Bufo; Anna Grimaldi; Michele Caraglia; Marina Di Domenico
Journal:  Cancer Biol Ther       Date:  2012-07-24       Impact factor: 4.742

5.  Comprehensive analysis of the MYB-NFIB gene fusion in salivary adenoid cystic carcinoma: Incidence, variability, and clinicopathologic significance.

Authors:  Yoshitsugu Mitani; Jie Li; Pulivarthi H Rao; Yi-Jue Zhao; Diana Bell; Scott M Lippman; Randal S Weber; Carlos Caulin; Adel K El-Naggar
Journal:  Clin Cancer Res       Date:  2010-08-11       Impact factor: 12.531

6.  EGFR L861Q mutation is a frequent feature of pulmonary mucoepidermoid carcinoma.

Authors:  Yongfeng Yu; Zhengbo Song; Hui Gao; Lei Zhu; Shun Lu; Jie Zhang; Qingquan Luo
Journal:  J Cancer Res Clin Oncol       Date:  2012-04-18       Impact factor: 4.553

7.  Unfavorable prognosis of CRTC1-MAML2 positive mucoepidermoid tumors with CDKN2A deletions.

Authors:  Sarah L Anzick; Wei-Dong Chen; Yoonsoo Park; Paul Meltzer; Diana Bell; Adel K El-Naggar; Frederic J Kaye
Journal:  Genes Chromosomes Cancer       Date:  2010-01       Impact factor: 5.006

8.  Molecular testing guideline for selection of lung cancer patients for EGFR and ALK tyrosine kinase inhibitors: guideline from the College of American Pathologists, International Association for the Study of Lung Cancer, and Association for Molecular Pathology.

Authors:  Neal I Lindeman; Philip T Cagle; Mary Beth Beasley; Dhananjay Arun Chitale; Sanja Dacic; Giuseppe Giaccone; Robert Brian Jenkins; David J Kwiatkowski; Juan-Sebastian Saldivar; Jeremy Squire; Erik Thunnissen; Marc Ladanyi
Journal:  J Thorac Oncol       Date:  2013-07       Impact factor: 15.609

9.  Molecular testing guideline for selection of lung cancer patients for EGFR and ALK tyrosine kinase inhibitors: guideline from the College of American Pathologists, International Association for the Study of Lung Cancer, and Association for Molecular Pathology.

Authors:  Neal I Lindeman; Philip T Cagle; Mary Beth Beasley; Dhananjay Arun Chitale; Sanja Dacic; Giuseppe Giaccone; Robert Brian Jenkins; David J Kwiatkowski; Juan-Sebastian Saldivar; Jeremy Squire; Erik Thunnissen; Marc Ladanyi
Journal:  Arch Pathol Lab Med       Date:  2013-04-03       Impact factor: 5.534

10.  Primary mucoepidermoid carcinoma of the lung with prominent clear cells.

Authors:  David D Fink; Angela M Lomas; Anja C Roden; Prashant C Shah; Riyam T Zreik
Journal:  Proc (Bayl Univ Med Cent)       Date:  2017-07
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.